NYSEARCA:IYH

iShares US Healthcare E.T.F. (IYH)

70.89
+0.89 (1.26%)
as of Aug 10, 2026, 6:42:15 pm Market Open.
20 watching
0
Investor Insights
star iconAug 10, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

The iShares US Healthcare ETF (IYH-N) appears to be on a positive trajectory as experts highlight improvements in Medical Loss Ratio (MLR) expectations for managed-care companies, which is a key metric indicating the profitability and efficiency of healthcare plans. Furthermore, there is anticipated clarity surrounding Medicare Advantage, suggesting a more favorable regulatory environment that could bolster managed-care operations. This combination of enhanced financial metrics and regulatory insight points to a potential uplift in the performance of healthcare stocks within this ETF. As these factors contribute to overall investor confidence, there are promising signs for growth and stability in the healthcare sector. Stakeholders are advised to monitor these developments closely as they may impact returns going forward.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
XLV
COMMENT

Healthcare tends to be a little less correlated to the equity market, so it is an ideal place to be. We are approaching the seasonal strength for biotech at the end of June. The chart on this is showing higher lows and higher highs. A similar one, but hedged to the Cdn$, would be BMO Equal Weight US Healthcare (ZUH-T). (See Top Picks.)

BUY

Owns all the large US healthcare names. Continues to move along at a very nice clip.

BUY

This has big holdings in things like Johnson & Johnson (JNJ-N), Pfizer (PFE-N), Merck (MRK-N), etc. Has done very well year to date.

BUY ON WEAKNESS
Likes this area. Going forward, it will be a defensive space. Broke out past its previous resistance point. If you own, Hold. You could add to that on pullbacks.
BUY
Have liked the sector for quite awhile. Has outperformed the S & P 500 since the beginning of the year. Very heavily weighted to large pharma. Short term there's a little bit of a risk, but long term, it's a place you want to have exposure to.
Showing 16 to 20 of 20 entries